KR20080038710A - Epidermal emulsion composition for treating a bald containing minoxidil and tretinoin - Google Patents
Epidermal emulsion composition for treating a bald containing minoxidil and tretinoin Download PDFInfo
- Publication number
- KR20080038710A KR20080038710A KR1020060105964A KR20060105964A KR20080038710A KR 20080038710 A KR20080038710 A KR 20080038710A KR 1020060105964 A KR1020060105964 A KR 1020060105964A KR 20060105964 A KR20060105964 A KR 20060105964A KR 20080038710 A KR20080038710 A KR 20080038710A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- acid
- minoxidil
- tretinoin
- total weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229960003632 minoxidil Drugs 0.000 title claims abstract description 43
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 title claims abstract description 34
- 229960001727 tretinoin Drugs 0.000 title claims abstract description 32
- 239000000839 emulsion Substances 0.000 title claims abstract description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000004090 dissolution Methods 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 235000019441 ethanol Nutrition 0.000 claims abstract description 9
- 239000000654 additive Substances 0.000 claims abstract description 8
- 235000011187 glycerol Nutrition 0.000 claims abstract description 8
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims abstract description 7
- 230000000996 additive effect Effects 0.000 claims abstract description 7
- 235000013772 propylene glycol Nutrition 0.000 claims abstract description 5
- 230000003779 hair growth Effects 0.000 claims description 21
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 14
- 235000021360 Myristic acid Nutrition 0.000 claims description 13
- 239000003655 absorption accelerator Substances 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical group CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
- 229940073665 octyldodecyl myristate Drugs 0.000 claims description 8
- -1 octyl dodecyl Chemical group 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 4
- 229920003083 Kollidon® VA64 Polymers 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 4
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- GECRRQVLQHRVNH-MRCUWXFGSA-N 2-octyldodecyl (z)-octadec-9-enoate Chemical compound CCCCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC GECRRQVLQHRVNH-MRCUWXFGSA-N 0.000 claims description 3
- ZIIVEKCKOPDBLT-UHFFFAOYSA-N 2-octyldodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCC(COC(=O)C(C)O)CCCCCCCC ZIIVEKCKOPDBLT-UHFFFAOYSA-N 0.000 claims description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 229960000583 acetic acid Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000001361 adipic acid Substances 0.000 claims description 3
- 235000011037 adipic acid Nutrition 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 229940077397 octyldodecyl lactate Drugs 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 239000001540 sodium lactate Substances 0.000 claims description 3
- 235000011088 sodium lactate Nutrition 0.000 claims description 3
- 229940005581 sodium lactate Drugs 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 2
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical group CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 230000003659 hair regrowth Effects 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 10
- 231100000274 skin absorption Toxicity 0.000 abstract description 8
- 230000037384 skin absorption Effects 0.000 abstract description 8
- 231100000245 skin permeability Toxicity 0.000 abstract description 6
- 210000004209 hair Anatomy 0.000 abstract description 5
- 210000002374 sebum Anatomy 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract 2
- 230000000052 comparative effect Effects 0.000 description 22
- 230000000694 effects Effects 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 6
- 201000004384 Alopecia Diseases 0.000 description 5
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 5
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- 208000024963 hair loss Diseases 0.000 description 5
- 230000003676 hair loss Effects 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 229960003604 testosterone Drugs 0.000 description 4
- 210000002268 wool Anatomy 0.000 description 4
- 230000001133 acceleration Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- YICVJSOYNBZJAK-UHFFFAOYSA-N 14-methylpentadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C YICVJSOYNBZJAK-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229940078568 isocetyl myristate Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- GKCWOKQJKLQXNZ-UHFFFAOYSA-N 2-butyltetradecanoic acid Chemical compound CCCCCCCCCCCCC(C(O)=O)CCCC GKCWOKQJKLQXNZ-UHFFFAOYSA-N 0.000 description 1
- CKPOABDCSSXDCY-UHFFFAOYSA-N 2-propan-2-yltetradecanoic acid Chemical compound CCCCCCCCCCCCC(C(C)C)C(O)=O CKPOABDCSSXDCY-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Abstract
Description
도1. 등부분의 털이 제모된후 테스토스테론 4.0중량% 용액을 일주일 동안 일 1회 도포하여 남성형 탈모 환경이 조성된 BDF1마우스에 대하여, 본원발명에 따른 비교예를 도포하기 전의 사진. Figure 1. Photograph before applying the comparative example according to the present invention to the BDF1 mouse in which the male hair loss environment was formed by applying the testosterone 4.0% by weight solution once a week for one week after hair removal on the back.
도2. 등부분의 털이 제모된후 테스토스테론 4.0중량% 용액을 일주일 동안 일 1회 도포하여 남성형 탈모 환경이 조성된 BDF1마우스에 대하여, 본원발명에 따른 실시예를 도포하기 전의 사진.Figure 2. Photograph before applying the Example according to the present invention to the BDF1 mouse in which the male hair loss environment was formed by applying the testosterone 4.0% by weight solution once a week for 1 week after hair removal on the back.
도3. 본원발명에 따른 비교예를 도포후 3주가 경과된 후 촬영된 BDF1 마우스 사진.Figure 3. BDF1 mouse photograph taken three weeks after the application of the comparative example according to the present invention.
도4. 본원발명에 따른 실시예를 도포후 3주가 경과된 후 촬영된 BDF1 마우스 사진.Figure 4. BDF1 mouse picture taken three weeks after application of the embodiment according to the present invention.
본 발명은 미녹시딜과 트레티노인을 함유하는 약학 조성물에 대하여, 피막형성제를 이용하여 피막형성을 통해 활성성분의 흡수를 돕고, 기름성분인 피지와 친 화성을 갖는 피부흡수촉진제를 이용하여 피부투과성이 향상된 외용 에멀젼 발모용 조성물 및 이의 제조방법에 관한 것이다. The present invention provides a pharmaceutical composition containing minoxidil and tretinoin, using the film forming agent to help the absorption of the active ingredient through the film formation, and improved skin permeability by using a skin absorption accelerator having affinity with oil sebum. The present invention relates to an emulsion composition for hair growth and a method for preparing the same.
더욱 상세하게는 본 발명은 미녹시딜과 트레티노인을 활성성분으로 하고, 에틸알코올, 프로필렌글리콜, 글리세린 또는 이들의 혼합물로 이루어진 군으로부터 선택되는 용해보조제 및 기타 첨가제(안정제, 보존제)가 포함되어 이루어지는 외용 에멀젼을 제공함으로써 발모용으로 사용 가능한 조성물 및 이의 제조방법에 관한 것이다.More specifically, the present invention provides an external emulsion comprising minoxidil and tretinoin as active ingredients, and a dissolution aid and other additives (stabilizer, preservative) selected from the group consisting of ethyl alcohol, propylene glycol, glycerin or mixtures thereof. It relates to a composition that can be used for hair growth by providing and a method for producing the same.
본 발명의 화합물인 미녹시딜(2,4-디아미노-6-피페리디노피리미딘-3-옥시드)은 본래는 경구용 고혈압 치료제로서 미국 식품 의약청 승인을 받은 이후, 혈관 확장제로써 중증의 고혈압 치료에 사용되어 왔는데, 이를 경구 투여한 환자에게서 체모의 성장, 굵어짐 및 색소 증가 현상이 나타난다는 사실이 발견되어 2%, 3%, 5% 농도의 미녹시딜이 현재 국소 도포용 제제로 개발되어 남성 탈모증 치료에 사용되고 있다.Minoxidil (2,4-diamino-6-piperidinopyrimidine-3-oxide), a compound of the present invention, was originally approved by the US Food and Drug Administration as a therapeutic agent for oral hypertension, followed by treatment of severe hypertension with vasodilators. It has been found that hair growth, thickening and pigmentation are observed in oral administration patients, and 2%, 3%, and 5% concentrations of minoxidil have been developed for topical application. It is used for treatment.
본 발명의 또 다른 화합물인 트레티노인(또는 올-트란스 레티온산 또는 비타민A 산)은 피부질환인 심상성 좌창에 사용되는 약물이다. 이 약물은 비타민 A를 원료로 만들어진 비타민A 합성 유도체로, 여드름 치료에 사용될 뿐 아니라 기미나 잡티 등의 색소치료에도 사용되고 있으며, 주름을 없애는 항노화 기능도 지닌 것으로 알려지면서 각광받고 있는 약물이다. Another compound of the invention, tretinoin (or all-trans retinoic acid or vitamin A acid), is a drug used for vulgar acne, a skin disease. This drug is a vitamin A synthetic derivative made from vitamin A as a raw material. It is used not only for the treatment of acne, but also for the treatment of pigments such as blemishes and blemishes, and is known to have anti-aging function to remove wrinkles.
또한 트레티노인은 최근 들어 미녹시딜의 흡수량을 높이고, 두피 부위에서 상피세포를 증가시킬 뿐 아니라 피부와 모낭을 재생시키고 새로운 활력을 불어넣어 주는 성분으로 알려져 미녹시딜과 함께 사용이 되어 왔고, 또 두피 부위에서 디히드로테스토스테론(DHT)의 수치를 감소시켜 이 DHT가 모낭에 추가적인 손상을 입히지 못하도록 억제해 주는 효과도 발휘한다고 알려졌다.In addition, tretinoin has recently been used with minoxidil to increase the absorption of minoxidil, increase epithelial cells in the scalp area, regenerate the skin and hair follicles, and invigorate new vitality. It has also been shown to reduce the levels of testosterone (DHT), which inhibits DHT from further damage to hair follicles.
현재 시판되는 여러 처방 약제는 미녹시딜 단일 용액 제제로서, 탈모환자들은 트레티노인 함유 용액을 도포한 후 미녹시딜 함유 제제를 도포 해야 하는 불편한 점이 있었다. 이에 본 발명에서는 두 약물을 안정성을 갖춘 한 제제로 바꾸어 탈모환자의 편의도를 높였다.Many prescription drugs currently on the market are minoxidil single solution formulations, and hair loss patients have to apply a minoxidil-containing formulation after applying a tretinoin-containing solution. Therefore, in the present invention, the convenience of the hair loss patient was increased by changing the two drugs into a stable formulation.
또한, 기존에는 미녹시딜 일반 용액 제제로서 미녹시딜에 대해 높은 용해력을 갖는 프로필렌글리콜과 에탄올, 물 등을 수성용매로 사용한 미녹시딜 액제를 사용하였다. 그런데, 이는 피부의 모낭을 둘러싸고 있는 기름 성분인 피지와 친화성이 없어 피부 투과성을 극히 저하시키는 문제점이 있다. 이에 본 발명에서는 미녹시딜과 트레티노인의 흡수 촉진을 위해 기름성분인 피지와 친화성을 갖는 피부흡수촉진제를 사용하여, 기존 제제의 문제점이었던 저조한 피부투과성을 개선시키고 재현성있는 피부흡수 효과를 얻을 수 있었다.In addition, a minoxidil solution using propylene glycol, ethanol, water, and the like as an aqueous solvent, which has a high solubility with respect to minoxidil, has been used as a conventional solution of minoxidil. However, there is a problem in that the skin permeability is extremely reduced because there is no affinity with sebum which is an oil component surrounding the hair follicles of the skin. Therefore, in the present invention, by using a skin absorption accelerator having affinity with oil component sebum to promote absorption of minoxidil and tretinoin, it was possible to improve poor skin permeability and reproducible skin absorption effect which was a problem of the conventional formulation.
또한 본 발명에서는 흡수 촉진의 극대화를 위하여 피막을 형성하는 물질인 히드록시프로필 메틸셀룰로오스, 메틸셀룰로오스, 프로필셀룰로오스, 폴리프로필렌, 폴리메틸메타크릴레이트 또는 이들의 혼합물로 이루어진 군을 선택하여 첨가함으로써, 활성성분인 미녹시딜과 트레티노인이 두피에 오래도록 분포되어 목적하는 피부 조직까지 효과적으로 도달하여 작용하도록 도와주도록 하여 본 발명을 완성하였다.In addition, in the present invention, by activating by selecting and adding a group consisting of hydroxypropyl methyl cellulose, methyl cellulose, propyl cellulose, polypropylene, polymethyl methacrylate, or a mixture thereof, which forms a film to maximize absorption, The components of minoxidil and tretinoin are distributed on the scalp for a long time to help effectively reach and function to the desired skin tissue, thereby completing the present invention.
이에 본 발명은 상기한 미녹시딜 함유제제와 트레티노인 함유제제를 따로 사용하는 불편을 해결하고, 기존 제제의 문제점인 저조한 피부투과성을 개선하며, 피막형성을 통한 지속 분포와 효과적 투과에 의한 보다 강력한 미녹시딜과 트레티노인을 함유한 외용 에멀젼 발모용 조성물을 만드는 데 목적이 있다. Accordingly, the present invention solves the inconvenience of using the minoxidil-containing agent and tretinoin-containing agent separately, improves poor skin permeability, which is a problem of the existing formulations, and more powerful minoxidil and tretinoin by continuous distribution and effective permeation through film formation. The purpose is to make a composition for external emulsion hair growth containing.
상기의 목적을 달성하기 위하여, 본발명에 따른 외용 에멀젼 발모용 조성물이 활성성분으로 미녹시딜 및 트레티노인을 함유하고 흡수촉진제, 피막형성제, 용해보조제 및 첨가제를 포함하여 이루어질 수 있다.In order to achieve the above object, the composition for external emulsion hair growth according to the present invention may contain minoxidil and tretinoin as active ingredients and may include an absorption accelerator, a film forming agent, a dissolution aid and an additive.
상기 발모용조성물은 미녹시딜이 조성물 전체 중량에 대하여 2.0중량% 내지 5.0중량%; 트레티노인이 조성물 전체 중량에 대하여 0.01중량% 내지 0.03중량%; 흡수촉진제가 조성물 전체 중량에 대하여 0.1중량% 내지 2.0중량%; 피막형성제가 조성물 전체 중량에 대하여 0.3중량% 내지 5.0중량%; 용해보조제가 조성물 전체 중량에 대하여 85.0중량% 내지 94.0중량%; 및 첨가제가 조성물 전체 중량에 대하여 0.05중량% 내지 2.0중량%;를 포함하여 이루어질 수 있다.The hair growth composition is minoxidil 2.0 to 5.0% by weight relative to the total weight of the composition; Tretinoin is 0.01% to 0.03% by weight based on the total weight of the composition; The absorption accelerator is 0.1% to 2.0% by weight based on the total weight of the composition; The film forming agent is 0.3% to 5.0% by weight based on the total weight of the composition; The dissolution aid is 85.0% to 94.0% by weight based on the total weight of the composition; And 0.05 wt% to 2.0 wt% with respect to the total weight of the composition.
상기 흡수촉진제가 옥틸도데실 미리스테이트, 젖산 옥틸도데실, 에르카산 옥틸 도데실, 올레산 옥틸도데실, 리시놀레산 옥틸도데실, 미리스트산 이소스테아르, 미리스트산 이소세틸, 미리스트산 이소프로필, 미리스트산 부틸, 미리스트산 세틸, 미리스트산 데실, 미리스트산 미리스틸 또는 이들의 혼합물로 이루어진 군으로 부터 선택될 수 있다.The absorption accelerator is octyldodecyl myristate, octyl dodecyl lactate, octyl dodecyl ercaate, octyl dodecyl oleate, octyledolic acid lysoleate, isostearic acid, Myristic acid isocetyl, myristic acid isopropyl, myristic acid butyl, myristic acid cetyl, It may be selected from the group consisting of myristic acid decyl, myristic acid myristyl or mixtures thereof.
상기 피막형성제가 히드록시프로필 메틸셀룰로오스, 메틸셀룰로오스, 프로필셀룰로오스, 폴리프로필렌, 폴리메틸메타크릴레이트 또는 이들의 혼합물로 이루어진 군으로 부터 선택될 수 있다.The film forming agent may be selected from the group consisting of hydroxypropyl methyl cellulose, methyl cellulose, propyl cellulose, polypropylene, polymethyl methacrylate or a mixture thereof.
상기 용해보조제가 에틸알코올, 글리세린, 프로필렌 글리콜, 크레모포르 RH40 또는 이들의 혼합물로 이루어지는 군으로 부터 선택될 수 있다.The dissolution aid may be selected from the group consisting of ethyl alcohol, glycerin, propylene glycol, cremophor RH40 or mixtures thereof.
상기 첨가제가 안정화제로서 Kollidon VA64, pH조절제로서 구연산, 젖산나트륨, 초산나트륨, 젖산, 빙초산 또는 아디핀산으로 이루어진 군으로 부터 선택되고, 항산화제로서 Butyl Hydroxy Anisole(이하 BHA), Butyl Hydroxy Toluene(이하 BHT), 토코페롤 또는 아스코르빈산으로 이루어진 군으로 부터 선택될 수 있다.The additive is selected from the group consisting of Kollidon VA64 as a stabilizer, citric acid, sodium lactate, sodium acetate, lactic acid, glacial acetic acid or adipic acid as a stabilizer, Butyl Hydroxy Anisole (hereinafter BHA), Butyl Hydroxy Toluene (hereinafter as BHT), tocopherol or ascorbic acid.
이하, 본 발명에 대하여 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.
본 발명에서는 활성 성분으로서, 미녹시딜은 전체 중량에 대하여 2.0 중량% 내지 5.0 중량%를 포함할 수 있다. 5.0 중량% 초과 포함 시에는 과다 투여에 의한 심장혈관에 영향을 주어 과도한 혈압 강하를 일으킬 수 있고, 2.0 중량% 미만 포함 시에는 기대하는 발모효과를 얻을 수 없다.In the present invention, as active ingredient, minoxidil may comprise 2.0% to 5.0% by weight based on the total weight. If it contains more than 5.0% by weight, it may affect the cardiovascular system due to overdose and cause excessive blood pressure drop. If it contains less than 2.0% by weight, the expected hair growth effect may not be obtained.
본 발명에서는 또 다른 활성 성분으로서, 트레티노인이 전체 중량에 대하여 0.01중량% 내지 0.03중량%, 더 바람직하게는 0.025 중량% 포함된다. 0.01중량% 미만으로 사용될 때에는 그 효과를 기대하기 어렵고, 0.03중량% 초과하여 사용하여도 함량증가에 따른 상승효과가 나타나지 않을 뿐더러, 과량 사용시 피부의 발적이나 가려움, 벗겨짐과 같은 부작용을 동반할 수 있다. 트레티노인이 사용될 때, 미녹시 딜의 흡수량을 높이고 두피 부위에서 상피세포를 증가시키고 피부와 모낭을 재생시키며, 디히드로테스토스테론(DHT)의 수치를 감소시켜 이 DHT가 모낭에 추가적인 손상을 입히지 못하도록 억제해 주는 효과가 있다.As another active ingredient in the present invention, tretinoin is included 0.01% to 0.03% by weight, more preferably 0.025% by weight based on the total weight. When used in less than 0.01% by weight it is difficult to expect the effect, even when used in excess of 0.03% by weight does not show a synergistic effect due to the increase in content, and may be accompanied by side effects such as redness, itching, peeling of the skin when used in excess . When tretinoin is used, it increases the absorption of minoxidil, increases epithelial cells in the scalp area, regenerates skin and hair follicles, and reduces the level of dehydrotestosterone (DHT), which prevents this DHT from causing further damage to hair follicles. Giving effect.
흡수촉진제로서는 옥틸도데실 미리스테이트, 젖산 옥틸도데실, 에르카산 옥틸 도데실, 올레산 옥틸도데실, 리시놀레산 옥틸도데실, 미리스트산 이소스테아르, 미리스트산 이소세틸, 미리스트산 이소프로필, 미리스트산 부틸, 미리스트산 세틸, 미리스트산 데실, 미리스트산 미리스틸 또는 이들의 혼합물로 이루어진 군으로 부터 선택되며, 본 발명 조성물 전체 중량에 대하여 0.1 중량% 내지 2.0 중량%가 포함될 수 있다. 2.0 중량% 초과 포함 시에는 제제의 제조 후 시간의 경과에 따라 층이 형성되는 등 제제의 안정성에 문제를 일으킬 수 있고, 0.1 중량% 미만 포함 시에는 원하는 흡수촉진제로의 역할을 기대하기 힘들다.Absorption accelerators octyldodecyl myristate, octyl dodecyl lactate, octyl dodecyl ercaate, octyl dodecyl oleate, octyledolic acid ricinoleate, isocetyl myristate, isocetyl myristate, isopropyl myristic acid It is selected from the group consisting of butyl myristic acid, myristic acid cetyl, myristic acid decyl, myristic acid myristyl, or a mixture thereof, and may include 0.1% to 2.0% by weight based on the total weight of the present composition. . If it contains more than 2.0% by weight, it may cause problems in the stability of the preparation, such as a layer is formed over time after the preparation of the preparation, when containing less than 0.1% by weight it is difficult to expect the role as the desired absorption accelerator.
본 발명에 따른 피막형성제로서는 히드록시프로필 메틸셀룰로오스, 메틸셀룰로오스, 프로필 셀룰로오스, 폴리프로필렌, 폴리메틸메타크릴레이트 또는 이들의 혼합물로 이루어진 군으로 부터 선택되며, 본 발명 조성물 전체 중량에 대하여 0.3 중량% 내지 5.0 중량%가 포함될 수 있다. 5.0 중량% 초과 첨가 시에는 조성물의 점도에 영향을 주고, 도포 시 피부의 당김 현상을 야기시킨다. 0.3 중량% 미만 첨가 시에는 피막형성 효과를 통한 분포지속 시간을 기대하기 힘들다.The film-forming agent according to the present invention is selected from the group consisting of hydroxypropyl methyl cellulose, methyl cellulose, propyl cellulose, polypropylene, polymethyl methacrylate or mixtures thereof, and 0.3 wt% based on the total weight of the composition of the present invention. To 5.0 wt%. Addition of more than 5.0% by weight affects the viscosity of the composition and causes a pulling of the skin upon application. If less than 0.3% by weight, it is difficult to expect the distribution duration through the film forming effect.
본 발명에 따른 용해보조제로서 에틸알코올, 글리세린, 프로필렌 글리콜, 크레모포르 RH40의 이들의 혼합물이 전체 중량에 대하여 85.0 중량% 내지 94.0 중량%가 포함될 수 있다. 에틸알코올과 글리세린은 미녹시딜의 용해제 및 용해보조제로 서의 역할을 하며, 프로필렌 글리콜과 크레모포르 RH40은 트레티노인과 옥틸도데실 미리스테이트를 위한 용해제 및 용해보조제로서의 역할을 한다. 94.0 중량% 초과 첨가 시에는 본 발명 조성물의 점도에 영향을 주어, 사용시 끈적임 등의 불편함을 야기 시킬 수 있고, 유층과 수층의 분리로 안정성에 문제를 발생시킨다. 85.0 중량% 미만 첨가 시에는 주성분의 용해가 어렵다.As a dissolution aid according to the present invention, a mixture of ethyl alcohol, glycerin, propylene glycol and cremophor RH40 may be included in an amount of 85.0 wt% to 94.0 wt% based on the total weight. Ethyl alcohol and glycerin serve as solubilizers and dissolution aids for minoxidil, and propylene glycol and cremophor RH40 serve as solubilizers and dissolution aids for tretinoin and octyldodecyl myristate. When added in excess of 94.0% by weight may affect the viscosity of the composition of the present invention, it may cause discomfort such as stickiness in use, and the problem of stability due to separation of the oil layer and the water layer. If less than 85.0% by weight of the main component is difficult to dissolve.
본 발명에 따른 안정제로서는 Kollidon VA64, pH조절제로서는 구연산, 젖산나트륨, 초산나트륨, 젖산, 빙초산 또는 아디핀산으로 이루어진 군으로 부터 선택되며, 항산화제로서 BHT, BHA, 토코페롤 또는 아스코르빈산으로 이루어진 군으로 부터 선택되고, 조성물 전체 중량에 대하여 0.05중량% 내지 2.0중량% 포함될 수 있다.The stabilizer according to the present invention is selected from the group consisting of Kollidon VA64, pH adjusting agent, citric acid, sodium lactate, sodium acetate, lactic acid, glacial acetic acid or adipic acid, and as an antioxidant is a group consisting of BHT, BHA, tocopherol or ascorbic acid It may be selected from, and may be included in the 0.05 wt% to 2.0 wt% based on the total weight of the composition.
이하 본 발명을 하기 실시예 및 비교예들에 의하여 더욱 상세하게 설명하고자 한다. 다만, 하기 실시예는 하나의 예시일 뿐, 이들에 의해서 본 발명의 범위가 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples and comparative examples. However, the following examples are merely examples and the scope of the present invention is not limited thereto.
[실시예]EXAMPLE
하기 표1의 조성대로 미녹시딜과 트레티노인 함유 외용 에멀젼 발모용 조성물을 제조하였다.Minoxidil and tretinoin-containing external emulsion hair growth composition was prepared according to the composition of Table 1 below.
[표1] Table 1
상기의 각 조성에 따라, 미녹시딜은 에틸알코올과 글리세린을 용해제로 사용하여 제조하였고, 트레티노인은 크레모포르 RH40과 프로필렌 글리콜을 용해제로 사용하여 50℃에서 제조하여, 두 제조된 용액을 서서히 혼합하여 조성물을 완성하였다. According to each of the above compositions, minoxidil was prepared using ethyl alcohol and glycerin as a dissolving agent, tretinoin was prepared at 50 ° C. using Cremophor RH40 and propylene glycol as a dissolving agent, and the two prepared solutions were slowly mixed. Was completed.
[비교예1]Comparative Example 1
상기 실시예의 조성에서 옥틸도데실 미리스테이트를 제외하고는 동일한 조성과 제조방법으로 비교예의 발모용 조성물을 제조하였다.Except for octyldodecyl myristate in the composition of the above example, the composition for hair growth of the comparative example was prepared by the same composition and preparation method.
[비교예2]Comparative Example 2
상기 실시예의 조성에서 트레티노인을 제외하고는 동일한 조성과 제조방법으로 비교예의 발모용 조성물을 제조하였다.Except for tretinoin in the composition of the above example, the composition for hair growth of the comparative example was prepared by the same composition and preparation method.
[비교예3]Comparative Example 3
상기 실시예의 조성에서 히드록시프로필 메틸셀룰로오스를 제외하고는 동일한 조성과 제조방법으로 비교예의 발모용 조성물을 제조하였다.Except for the hydroxypropyl methyl cellulose in the composition of the Example was prepared a composition for hair growth of the comparative example in the same composition and preparation method.
[비교예4]Comparative Example 4
상기 실시예의 조성에서 옥틸도데실 미리스테이트, 히드록시프로필 메틸셀룰 로오스를 제외하고는 동일한 조성과 제조방법으로 비교예4의 발모용 조성물을 제조하였다.Except for octyldodecyl myristate and hydroxypropyl methylcellulose in the composition of the above Example, the composition for hair growth of Comparative Example 4 was prepared by the same composition and preparation method.
[비교예5]Comparative Example 5
상기 실시예의 조성에서 트레티노인, 히드록시프로필 메틸셀룰로오스를 제외하고는 동일한 조성과 제조방법으로 비교예5의 발모용 조성물을 제조하였다.Except for tretinoin and hydroxypropyl methylcellulose in the composition of the above example, the composition for hair growth of Comparative Example 5 was prepared by the same composition and preparation method.
[시험예1][Test Example 1]
본원발명에 따른 상기 실시예 대하여 실온, 냉장 및 가속의 조건하에서 보관 기간에 따른 두 활성성분인 미녹시딜과 트레티노인의 안정성을 확인하였으며, 그 결과를 하기 표2에 나타내었다.The above embodiment according to the present invention was confirmed the stability of the two active ingredients minoxidil and tretinoin over the storage period under the conditions of room temperature, refrigeration and acceleration, the results are shown in Table 2 below.
[표2][Table 2]
(함량은 0주 대비 %로 환산하였다)(Content was converted into% compared to 0 weeks)
상기 표2에서 알 수 있듯이, 본 발명에 따라 실시예의 조성물로 제조 시 실온, 냉장 및 가속 조건에서 안정함을 확인할 수 있었다.As can be seen in Table 2, when the composition of the present invention according to the present invention was confirmed to be stable at room temperature, refrigeration and acceleration conditions.
[시험예2][Test Example 2]
본 발명에 따른 실시예에 대하여, 옥틸도데실 미리스테이트의 미녹시딜 성분의 피부흡수촉진효과를 확인하였으며 그 결과를 하기 표3에 나타내었다.For the Example according to the present invention, the skin absorption promoting effect of the minoxidil component of octyldodecyl myristate was confirmed and the results are shown in Table 3 below.
[표3]Table 3
주 : 미녹시딜의 누적 피부투과량(㎍/㎠) = 검액의 농도(㎍/㎖) X 셀의 전체용적(㎖)X(1/셀의 입구면적(㎠))Note: Cumulative skin permeation of minoxidil (㎍ / ㎠) = concentration of sample solution (㎍ / mL) X total volume of cells (mL) X (1 / cell inlet area (㎠))
상기 표3의 결과로부터 알 수 있는 바와 같이 본 발명의 조성물은 비교예1 및 비교예4에 비해 우수한 피부투과능을 나타낸다. 또한 비교예1은 본원발명에 따른 실시예를 비교 시, 12시간 경과 후, 약 1.31배 이상의 증가된 흡수를 나타내는 것을 알 수 있었다. As can be seen from the results of Table 3, the composition of the present invention shows excellent skin permeability compared to Comparative Example 1 and Comparative Example 4. In addition, Comparative Example 1 was found to show an increased absorption of about 1.31 times or more after 12 hours, when comparing the Example according to the present invention.
[시험예3][Test Example 3]
본 발명의 실시예에 대하여 미녹시딜 단독 사용과의 비교를 통해 발모 및 양모 효과를 확인하였다. For the examples of the present invention, the hair growth and wool effects were confirmed through comparison with minoxidil alone.
시험은 BDF1 마우스(4주령)의 등부분 털을 제모 후 테스토스테론 4.0 중량% 용액을 일주일 동안 일 1회 도포하여 남성형 탈모 환경을 조성 후(도1 및 도2참조), 실시예와 비교예2를 1일 2회 3주간 도포하여 발모 및 양모 효과를 확인하였다. The test was conducted after depilation of the back hairs of BDF1 mice (4 weeks old) and application of testosterone 4.0% by weight solution once a week to form a male hair loss environment (see FIGS. 1 and 2). It was applied twice a day for 3 weeks to check the hair growth and wool effect.
상기 시험을 통해 미녹시딜의 단독 사용보다(도3 참조)는 트레티노인과의 병용 사용(도4참조)이 더욱 양모 및 발모에 효과적임을 알 수 있으며, 이에 본 발명의 조성물은 단독 제제로 각각 사용시의 번거로움을 없애고 사용 시 편의성을 향상 시켰다.Through the above test, it can be seen that the combined use of tretinoin (see Fig. 4) is more effective for wool and hair growth than the use of minoxidil alone (see Fig. 3). Removed the convenience and improved the ease of use.
[시험예4][Test Example 4]
본 발명에서는 미녹시딜과 트레티노인의 피막형성제 사용을 통한 지속분포시간의 증대를 통한 미녹시딜의 흡수 증가를 확인하였으며, 그 결과를 하기 표4에 나타내었다.In the present invention, the absorption of minoxidil was confirmed by increasing the sustained distribution time through the use of the film forming agent of minoxidil and tretinoin, and the results are shown in Table 4 below.
[표4]Table 4
주 : 미녹시딜의 누적 피부투과량(㎍/㎠) = 검액의 농도(㎍/㎖) X 셀의 전체용적(㎖)X(1/셀의 입구면적(㎠))Note: Cumulative skin permeation of minoxidil (㎍ / ㎠) = concentration of sample solution (㎍ / mL) X total volume of cells (mL) X (1 / cell inlet area (㎠))
상기 표4의 결과로부터 알 수 있는 바와 같이, 본 발명의 따른 실시예는 피막형성제를 제외했을 때(비교예3) 보다 첨가한 경우가 더 좋은 결과를 보였으며, 이는 피부흡수촉진제인 옥틸도데실 미리스테이트만(비교예5)을 첨가한 경우보다 더 나은 효과를 나타내었다.As can be seen from the results of Table 4, the embodiment according to the present invention showed a better result than when the film forming agent was excluded (Comparative Example 3), which is octyldode as a skin absorption accelerator. It showed a better effect than the addition of only sil myristate (Comparative Example 5).
본 발명의 외용 에멀젼 제제는 활성성분으로 미녹시딜과 트레티노인을 포함하고 흡수 증가를 위해 기름성분인 피지와 친화성을 갖는 피부흡수촉진제를 함유하여 미녹시딜 성분의 피부흡수력을 촉진시켜 발모 및 양모의 측면에서 우수한 활성을 나타내고, 피막을 형성시켜 유효성분이 두피에 오래도록 분포케 하여 좋은 효과 를 발휘한다. 또한 트레티노인과 함께 제조되어 따로 도포해야 하는 번거로움을 없애 환자의 편의성을 향상시켰다. 또한 적절한 첨가제를 사용하여 보관 시에도 성상의 변화가 없고 함량도 거의 감소되지 않는 장점을 지니고 있는 외용 발모용 에멀젼 조성물이다.The external emulsion formulation of the present invention contains minoxidil and tretinoin as active ingredients and contains a skin absorption accelerator having an affinity with oil sebum for increasing absorption, thereby promoting skin absorption of minoxidil component and thus excellent in terms of hair growth and wool. It shows activity, forms a film, and distributes the active ingredient to the scalp for a long time. In addition, it is manufactured with tretinoin to improve the patient's convenience by eliminating the need to apply separately. In addition, it is an emulsion composition for external hair regrowth having the advantage that there is no change in properties even when stored with an appropriate additive and the content is not reduced.
상기에서 본 발명은 기재된 구체적인 예들을 중심으로 상세히 설명되었지만, 본 발명의 범주 및 기술사상 범위 내에서 다양한 변형 및 수정이 가능함은 당 업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.Although the present invention has been described in detail with reference to specific examples described, it will be apparent to those skilled in the art that various modifications and variations are possible within the scope and spirit of the present invention, and such modifications and modifications are set forth in the appended claims. It is natural to belong.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060105964A KR20080038710A (en) | 2006-10-31 | 2006-10-31 | Epidermal emulsion composition for treating a bald containing minoxidil and tretinoin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060105964A KR20080038710A (en) | 2006-10-31 | 2006-10-31 | Epidermal emulsion composition for treating a bald containing minoxidil and tretinoin |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20080038710A true KR20080038710A (en) | 2008-05-07 |
Family
ID=39647128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060105964A KR20080038710A (en) | 2006-10-31 | 2006-10-31 | Epidermal emulsion composition for treating a bald containing minoxidil and tretinoin |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20080038710A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012040342A2 (en) * | 2010-09-21 | 2012-03-29 | Conrex Pharmaceutical Corporation | Restoration of hair |
KR20170018967A (en) * | 2014-06-30 | 2017-02-20 | 존슨 앤드 존슨 컨수머 인코포레이티드 | Minoxidil-containing hair growth composition |
JP2019501219A (en) * | 2015-12-28 | 2019-01-17 | ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドJohnson & Johnson Consumer Inc. | Hair growth composition and method |
FR3070688A1 (en) * | 2017-09-07 | 2019-03-08 | Jean-Paul Djian | DERMATOLOGICAL COMPOSITION FOR TREATING ALOPECIA |
KR20190048236A (en) | 2017-10-31 | 2019-05-09 | 정한수 | Shampoo composite for hair loss preventation with multilayer nanoparticles that encapsulate poorly water soluble natural drug and manufacturing method therefore |
KR20210042525A (en) | 2019-10-10 | 2021-04-20 | 한스텍주식회사 | Shampoo composite for hair loss preventation by using natural material extracts and manufacturing method therefore |
-
2006
- 2006-10-31 KR KR1020060105964A patent/KR20080038710A/en not_active Application Discontinuation
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012040342A2 (en) * | 2010-09-21 | 2012-03-29 | Conrex Pharmaceutical Corporation | Restoration of hair |
WO2012040342A3 (en) * | 2010-09-21 | 2012-06-21 | Conrex Pharmaceutical Corporation | Restoration of hair |
US11000466B2 (en) | 2014-06-30 | 2021-05-11 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
JP2020180165A (en) * | 2014-06-30 | 2020-11-05 | ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドJohnson & Johnson Consumer Inc. | Minoxidil-containing hair growth composition |
EP3160438B1 (en) * | 2014-06-30 | 2024-02-28 | Johnson & Johnson Consumer Inc. | Minoxidil-containing hair growth composition |
JP2017524684A (en) * | 2014-06-30 | 2017-08-31 | ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドJohnson & Johnson Consumer Inc. | Hair growth composition containing minoxidil |
KR20170018967A (en) * | 2014-06-30 | 2017-02-20 | 존슨 앤드 존슨 컨수머 인코포레이티드 | Minoxidil-containing hair growth composition |
JP2019178174A (en) * | 2014-06-30 | 2019-10-17 | ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドJohnson & Johnson Consumer Inc. | Minoxidil-containing hair growth composition |
JP2020180164A (en) * | 2014-06-30 | 2020-11-05 | ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドJohnson & Johnson Consumer Inc. | Minoxidil-containing hair growth composition |
JP2021152066A (en) * | 2015-12-28 | 2021-09-30 | ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドJohnson & Johnson Consumer Inc. | Hair growth compositions |
US10925824B2 (en) | 2015-12-28 | 2021-02-23 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
US11039996B2 (en) | 2015-12-28 | 2021-06-22 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
JP2021152065A (en) * | 2015-12-28 | 2021-09-30 | ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドJohnson & Johnson Consumer Inc. | Hair growth compositions |
US11185487B2 (en) | 2015-12-28 | 2021-11-30 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
US11666520B2 (en) | 2015-12-28 | 2023-06-06 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
JP2019501219A (en) * | 2015-12-28 | 2019-01-17 | ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドJohnson & Johnson Consumer Inc. | Hair growth composition and method |
FR3070688A1 (en) * | 2017-09-07 | 2019-03-08 | Jean-Paul Djian | DERMATOLOGICAL COMPOSITION FOR TREATING ALOPECIA |
KR20190048236A (en) | 2017-10-31 | 2019-05-09 | 정한수 | Shampoo composite for hair loss preventation with multilayer nanoparticles that encapsulate poorly water soluble natural drug and manufacturing method therefore |
KR20210042525A (en) | 2019-10-10 | 2021-04-20 | 한스텍주식회사 | Shampoo composite for hair loss preventation by using natural material extracts and manufacturing method therefore |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2498783B1 (en) | Compositions and methods for stimulating hair growth | |
KR100836002B1 (en) | Topical administration carrier composition and therapeutic formulations comprising same | |
EP2307031B1 (en) | Finasteride formulations for drug release to hair and scalp | |
DK1890732T3 (en) | TOPICAL VASO CONSTRUCTOR PREPARATIONS AND METHODS FOR PROTECTING CELLS UNDER CANCER THERAPY AND RADIATION THERAPY | |
EP2640350B1 (en) | Compositions and methods for hair growth | |
WO2011053801A2 (en) | Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye | |
JP2005314323A (en) | Hair growth formulation | |
EP2001460A2 (en) | Compositions for promoting hair growth | |
EA024483B1 (en) | Topical composition for treatment of hyperkeratotic skin | |
KR20080038710A (en) | Epidermal emulsion composition for treating a bald containing minoxidil and tretinoin | |
EP2255782A1 (en) | Composition for the prevention or treatment of hair loss, and method of preparation | |
US20060100287A1 (en) | Insulin-like growth factor-1 secretagogue | |
JPH1192378A (en) | Hair tonic liquid for external use | |
KR20210065968A (en) | Iron Chelating Compounds for Treating Aesthetic Skin Conditions | |
JP2000198719A (en) | Hair growing agent | |
JP5754565B2 (en) | Hair restorer composition, effect enhancer for hair restorer and method for producing hair restorer | |
US20150118292A1 (en) | Compositions and methods for treatment of hair loss | |
CN112190576A (en) | Composition of skin external preparation, skin external preparation and preparation method thereof | |
JPH11302133A (en) | Cosmetic for scalp and hair | |
CN114366687B (en) | Application of isophthalic acid in promoting hair growth | |
CN112043627B (en) | Amino acid solution composition for hair growth and preparation method thereof | |
KR20170121454A (en) | Fermented Extract Promoting Hair Growth-Hydrogel Nanoparticle Hybrid and Method for Preparing the Same | |
KR100292143B1 (en) | Cosmetic composition comprising glycollic acid and vitamin C | |
WO2021240163A1 (en) | Compounds, compositions and methods for the treatment or prevention of hair loss | |
JP4485133B2 (en) | Absorption enhancing composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Withdrawal due to no request for examination |